Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-07-24 EDT 5-day change 1st Jan Change
6,733.00 JPY -2.31% Intraday chart for Shionogi & Co., Ltd. +1.63% -0.96%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Jefferies Adjusts Shionogi's Price Target to 7,400 Yen From 7,600 Yen, Keeps at Hold MT
GSK Unit Says Dovato 'Non-Inferior' to Biktarvy in Phase 4 HIV Study MT
GSK Unit's Late-stage Study Shows HIV Prevention Drug's Efficacy, Safety in Pregnant Patients MT
Shionogi & Co Completes 449.6 Million Yen Disposal of Treasury Shares MT
Shionogi & Co., Ltd. Announces Progress on the Development Program for Zatolmilast CI
Japanese Shares Close Higher as Officials Address Yen Volatility Concerns MT
Shionogi & Co Introduces Covgoze Vaccine for Covid-19 in Japan MT
Shionogi & Co., Ltd. Obtains Domestic Manufacturing and Sales Approval for COVGOZE® CI
Shionogi & Co. to Dispose of 450 Million Yen Worth of Shares as Restricted Stock Compensation MT
Japan's Nikkei little changed ahead of key US data, central bank meetings RE
Japan's Nikkei edges down ahead of key US data, central bank meetings RE
Japan's Nikkei drifts sideways as more earnings, US CPI awaited RE
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial RE
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd CI
Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares MT
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol) CI
Shionogi Completes Up to 75 Billion Yen Share Buyback MT
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023. CI
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million. CI
FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd. CI
GSK Unit ViiV Healthcare's Injectable HIV Treatment Shows 'Superior Efficacy' in Late-stage Trial MT
Shionogi Buys Back Shares Worth Nearly 12 Billion Yen MT
GSK says ViiV's cabotegravir study supports longer HIV dose interval AN
GSK's ViiV Healthcare Says Four-month Interval Between Doses Possible for HIV Treatment Cabotegravir MT
Chart Shionogi & Co., Ltd.
More charts
Logo Shionogi & Co., Ltd.
Shionogi & Co., Ltd. specializes in development, manufacturing and marketing of pharmaceutical products. The group's activity is organized around 3 families of products: - prescription products: drugs for the treatment of cardiovascular and infectious diseases, diabetes, allergic reactions, etc.; - OTC products: analgesic products, vitamins and tonics, etc.; - diagnosis products: primarily for detection and treatment of cardiovascular diseases and immune system.
Employees
4,959
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
6,892.00JPY
Average target price
7,509.23JPY
Spread / Average Target
+8.96%
Consensus
  1. Stock Market
  2. Equities
  3. 4507 Stock
  4. News Shionogi & Co., Ltd.
  5. Shionogi & Co Introduces Covgoze Vaccine for Covid-19 in Japan